An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

This study tests apalutamide — a hormone-blocking drug — given before surgery (as neoadjuvant therapy) in men with high-risk or oligometastatic prostate cancer (cancer that has spread to a limited number of locations) to see if it can improve outcomes when combined with surgery and standard hormone therapy. **You may be eligible if...** - You are a man over 18 with confirmed prostate cancer - Your cancer is classified as high-risk based on test results - You are scheduled for minimally invasive radical prostatectomy (prostate removal surgery) - You are in good physical condition (ECOG 0–1) - You have agreed to receive both pre- and post-surgical hormone therapy **You may NOT be eligible if...** - You have another tumor requiring treatment - Imaging shows spread to organs like the liver or brain, or risk of spinal cord paralysis - You have a history of epilepsy or seizures - You have severe liver, kidney, heart, or vascular disease Talk to your doctor to see if this trial is right for you.